AstraZeneca and Amgen secure FDA breakthrough designation for asthma drug tezepelumab
In a significant advancement for asthma treatment, AstraZeneca, in partnership with Amgen, has received the coveted breakthrough therapy designation from the US Food and Drug Administration (FDA) for their innovative asthma drug, tezepelumab. This designation is specifically for the treatment of patients with severe asthma who do not exhibit an eosinophilic phenotype and are being […]